---
document_datetime: 2023-09-21 20:06:23
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/picato-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: picato-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.7238266
conversion_datetime: 2025-12-24 03:29:05.601821
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Picato

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                           | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                      |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------|
| A20/0030             | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 3 September 2019 the opinion of the European Medicines Agency further to an imbalance in skin tumour incidence in the treatment area noted in several studies. The CHMP was requested to assess the impact thereof on the benefit-risk balance of Picato and to give its recommendation whether the | 30/04/2020                                  | 02/07/2020                                  |                                  | Please refer to the assessment report: Picato EMEA/H/A-20/1489/C/002275/0030 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | marketing authorisation of this product should be maintained, varied, suspended or revoked.                                                                                      |                    |                   |                                  |                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10035 /201907 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                   | 13/02/2020         |                   |                                  | The PRAC noted the European Commission (EC) decision dated 11 February 2020 withdrawing the marketing authorisation(s) for Picato (ingenol mebutate) at the MAH's request. authorised |
| PSUSA/10035 /201901 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                   | 09/09/2019         | 11/11/2019        | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10035/201901.                                            |
| PSUSA/10035 /201807 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                   | 28/02/2019         | 26/04/2019 longer | Annex II                         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10035/201807.                                            |
| PSUSA/10035 /201801 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                   | 06/09/2018         | n/a no            |                                  | PRAC Recommendation - maintenance                                                                                                                                                     |
| PSUSA/10035 /201707 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                   | 08/02/2018 product | n/a               |                                  | PRAC Recommendation - maintenance                                                                                                                                                     |
| PSUSA/10035 /201701 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                   | 01/09/2017         | n/a               |                                  | PRAC Recommendation - maintenance                                                                                                                                                     |
| IB/0025             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data Medicinal | 24/08/2017         | n/a               |                                  |                                                                                                                                                                                       |
| R/0023              | Renewal of the marketing authorisation.                                                                                                                                          | 18/05/2017         | 13/07/2017        | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Picato in the approved indication remains favourable and therefore  |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        | recommended the renewal of the marketing authorisation with unlimited validity.                                                                       |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10035 /201607 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/02/2017 | 20/04/2017 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10035/201607. authorised |
| T/0022              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/12/2016 | 26/01/2017 | SmPC, Labelling and PL |                                                                                                                                                       |
| PSUSA/10035 /201601 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/09/2016 | 11/11/2016 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10035/201601.            |
| IB/0020/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue product | 18/07/2016 | n/a no     | longer                 |                                                                                                                                                       |
| IB/0019             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/07/2016 | n/a        |                        |                                                                                                                                                       |
| IA/0018/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15/06/2016 | n/a        |                        |                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | authorised                                                                                                                                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016/G           | This was an application for a group of variations. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a safety or quality issue B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) Medicinal product | 28/04/2016 | n/a no     | longer      |                                                                                                                                                              |
| PSUSA/10035 /201507 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/02/2016 | 25/04/2016 | SmPC and PL | Please refer to Picato-PSUSA/00010035/201507 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |

<div style=\"page-break-after: always\"></div>

| PSUSA/10035 /201501   | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/09/2015   | n/a           |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012               | Update of sections 4.2, 4.8 and 5.1 of the SmPC to provide new efficacy and safety based on clinical trial LP0041-22. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor linguistic amendments. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/06/2015   | 31/07/2015    | SmPC and PL longer | The results of LP0041-22 study which evaluated the effects of retreatment with Picato have been submitted by the MAH. Based on the results from this study as well as another study which evaluated simultaneous treatment of two areas with ingenol mebutate, update of sections 4.2, 4.8 and 5.1 of the SmPC to provide new efficacy and safety based on these studies have been performed. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor linguistic amendments. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). authorised |
| II/0013               | Update sections 4.8 and 5.1 of the SmPC to provide new efficacy and safety data supporting the addition of information to the Summary of Product Characteristics (SmPC) regarding the use of ingenol mebutate gel for treatment after cryotherapy. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product                                                                                                                                                                              | 25/06/2015   | 31/07/2015 no | SmPC               | This variation concerns the update of the SmPC to reflect clinical data from the clinical trial LP0041-21 (A Sequential Treatment Regimen of Cryotherapy and Picato (lngenol Mebutate) gel, 0.015% Field Therapy Compared to Cryotherapy Alone for the Treatment of Actinic Keratosis (AK) on the Face and Scalp). An update is suggested to sections 4.8 and 5.1 of the SmPC to provide new efficacy and safety data supporting the addition of information to the Summary of Product Characteristics (SmPC) regarding the use of ingenol mebutate gel for treatment after cryotherapy.                                                                                                                                   |
| II/0011               | Submission of the Clinical Study Report of study LP0041-62 ('Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment with Ingenol Mebutate Gel, 0.05%') to fulfil a Medicinal                                                                                                                                                                                                                                                                                                                                            | 23/04/2015   | n/a           |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | post-authorisation measure (LEG 003.1). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                  |                    |        | authorised                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------|-----------------------------------|
| PSUSA/10035 /201407 | Periodic Safety Update EU Single assessment - ingenol mebutate                                                                                                                                                                                                                                                                                                                                                                                                         | 12/02/2015         | n/a    | PRAC Recommendation - maintenance |
| IB/0008/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 02/10/2014         | n/a no | longer                            |
| PSUV/0005           | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/09/2014 product | n/a    | PRAC Recommendation - maintenance |
| IA/0007             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                          | 12/08/2014         | n/a    |                                   |
| IB/0006             | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method Medicinal                                                                                                                                                                                                                                        | 26/05/2014         | n/a    |                                   |

<div style=\"page-break-after: always\"></div>

| PSUV/0004   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/02/2014         | n/a           | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002     | Update of sections 4.8 and 5.1 of the SmPC based on the post marketing experience with Picato. The Package Leaflet was proposed to be updated accordingly. In addition, the MAH proposed to update section 4.6 of the SmPC for clarity reasons and to make one editorial change in section 4.5 of the SmPC. The MAH also took the opportunity to bring the PI in line with the latest QRD template (version 9.0) and to add the contact details of the Croatian local representative in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/11/2013 product | 15/01/2015 no | Annex Labelling PL Reported eye disorders, including the events of periorbital oedema and eyelid oedema may also occur after correctly applied facial treatment with Picato, and not necessarily only as a consequence of accidental direct exposure to the eye. Most eye disorders are understood as developing from gravitation of the commonly occurring application site swelling in the application site in to the eye area. To better describe the situation that eye disorders may occur after normal application an explanatory note has been inserted as a footnote under Table 1 in section 4.8 of the SmPC. After approximately 6 months of marketing experience with Picato, the non-serious event ''application site burning'' was among the most frequently reported spontaneous events. Therefore it was added as a footnote in section 4.8 of the SmPC. It was considered important to highlight that Picato leads to production of proinflammatory cytokines and chemokines and this was added in section 5.1 of the SmPC. In addition, the MAH proposed to update section 4.6 of the SmPC for clarity reasons and to make one editorial change in section 4.5 of the SmPC. The MAH also took the opportunity to bring the PI in line with the latest QRD template (version 9.0) and to add the contact details of the Croatian local representative in the Package longer authorised |
| IA/0003     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/09/2013         | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->